10-QPeriod: Q3 FY2008

ALNYLAM PHARMACEUTICALS, INC. Quarterly Report for Q3 Ended Sep 30, 2008

Filed November 7, 2008For Securities:ALNY

Summary

ALNYLAM PHARMACEUTICALS, INC. (ALNY) filed its Form 10-Q for the period ending September 30, 2008, reporting its unaudited financial results. As a clinical-stage biopharmaceutical company, ALNY's financial performance is primarily driven by research and development activities and its ability to secure funding. Investors should note that at this stage, the company is not generating significant revenue from product sales, and its financial statements reflect substantial operating losses and a reliance on cash reserves and potential future financing. The report details the company's condensed consolidated balance sheets, statements of operations, and cash flows. Key financial metrics to monitor include cash and cash equivalents, the burn rate of operating expenses, and the progress of its drug development pipeline. The accompanying Management's Discussion and Analysis (MD&A) section will provide crucial context on the company's financial condition, liquidity, and the risks associated with its drug development programs. Investors should pay close attention to the risk factors disclosed, as they highlight the inherent uncertainties and challenges in the pharmaceutical industry, particularly for companies in the early stages of development.

Key Highlights

  • 1ALNY is presenting its unaudited financial results for the third quarter and nine months ended September 30, 2008.
  • 2The company is a clinical-stage biopharmaceutical firm, meaning its financial statements reflect significant research and development expenses rather than product revenues.
  • 3Investors should closely examine the company's cash position and burn rate as indicators of financial health and runway.
  • 4The filing includes condensed consolidated balance sheets, statements of operations, and cash flows, providing a snapshot of the company's financial standing.
  • 5Management's Discussion and Analysis (MD&A) will offer insights into financial condition, liquidity, and operational results.
  • 6Risk Factors section is critical for understanding the inherent uncertainties and challenges in ALNY's drug development process and the broader biopharmaceutical industry.

Frequently Asked Questions

As a clinical-stage biopharmaceutical company, ALNY is not generating significant revenue from product sales at this time. Its financial statements primarily reflect expenses related to research and development activities.

The filing will provide details on ALNY's cash and cash equivalents on its balance sheet. Investors should review the condensed consolidated statements of cash flows and the MD&A to understand the company's cash burn rate and its ability to fund operations through its existing cash reserves or future financing activities.

The 'Risk Factors' section (Item 1A) is essential for understanding the specific risks ALNY faces. These typically include the inherent uncertainties in drug development, regulatory approval processes, competition, intellectual property protection, and the ability to secure future funding.

The financial statements are labeled 'unaudited' because they are prepared for interim periods (quarterly) and have not undergone a full audit by an independent accounting firm as typically performed for annual financial statements. While subject to review, they may contain fewer detailed disclosures and are subject to potential adjustments in the audited annual report.